Item 2.02 - Results of Operations and Financial Condition: Elevance Health, Inc. issued a press release on January 28, 2026, reporting its fourth quarter and full year 2025 financial results Exhibit 99.1: A copy of the earnings press release is furnished as an exhibit and incorporated by reference into the filing Filing Date: Current report filed on January 28, 2026, for the earliest event…

Our analysis rates this filing CAUTIOUS. Elevance Health presents an elevated concern profile driven by multiple material headwinds converging in 2026. The most significant concern is the explicit earnings guidance deceleration—GAAP EPS declining 11.5% and adjusted EPS growth of only 15.9%—combined…

Concern level: HIGH (6.8/10). Key factors: Two new high-severity risks identified (2026 EPS Growth Deceleration and Cybersecurity/Data Security at severity 7/10 each); Material earnings guidance deceleration: FY 2026 GAAP EPS declining 11.5% YoY and adjusted EPS growth of only 15.9%, falling below the company's stated 12%+ long-term target, signaling near-term operational headwinds; Explicit…

Notable risk changes: 2026 EPS guidance shows significant deceleration: GAAP EPS declining 11.5% YoY and adjusted EPS growth of only 15.9%, below the 12%+ long-term target the company expects to achieve in 2027, signaling near-term operational headwinds; Segment margin targets being 'recalibrated' downward, indicating management's prior profitability expectations are no longer achievable and suggesting competitive…

The model predicts ELV will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.